Also listed on Inozyme Pharma, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends no later than Mar 11, 2031 · Medium confidence
20-year base term ends Mar 11, 2031
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Mar 11, 2011
Mar 11, 2031
Jan 10, 2017
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 11, 2011, when application PCT/US2011/028233, the earliest non-provisional in its chain, was filed (this one was filed Aug 1, 2014) | Mar 11, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Mar 11, 2031 | Medium confidence |
This family
| Application PCT/US2011/028233 | PCT application no patent term | no patent term |
| US 8,846,603 | In force Mar 2031 | Mar 2031 |
| Application 14/004,294 | Abandoned not computed | not computed |
| US 9,540,621 | this patent no later than Mar 2031 | no later than Mar 2031 |
| Application 15/417,590 | Abandoned not computed | not computed |
| Application 17/105,245 | Abandoned not computed | not computed |
| Application 17/819,065 | Abandoned not computed | not computed |
| Application 19/183,431 | Pending not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 15, 2016 Reel 40329, frame 154 | Synageva Biopharma Corp.; Galaxy Merger Sub LLC | Alexion Pharma LLC | Merger and Change of Name |
| Nov 17, 2016 Reel 40361, frame 470 | Alexion Pharma LLC | Alexion Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Nov 23, 2020 Reel 54449, frame 251 | Alexion Pharmaceuticals, Inc. | Inozyme Pharma, Inc. | Assignment of Assignor's Interest |
| Aug 9, 2021 Reel 57127, frame 791 | Alexion Pharma LLC | Alexion Pharmaceuticals, Inc. | Corrective Assignment to Correct the Execution Date of the Assignment Previously Recorded at Reel: 040361 Frame: 0470. Assignor(S) Hereby Confirms the Assignment. |
| Nov 25, 2025 Reel 73707, frame 488 | Inozyme Pharma, Inc. | Biomarin Pharmaceutical Inc. | Assignment of Assignor's Interest |
| Apr 27, 2026 Reel 75493, frame 968 | Biomarin Pharmaceutical Inc.; Amicus Therapeutics, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Mar 11, 2031. We will not guess the cap.